OncoMatch/Clinical Trials/NCT07760012
68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
Is NCT07760012 recruiting? Yes, currently enrolling (Sep 2026). This NA trial studies non-drug interventions for melanoma (skin cancer).
This prospective, single-center, open-label exploratory diagnostic study aims to evaluate the safety, feasibility, and diagnostic performance of the novel Sortilin-targeted PET tracer 68Ga-SorB in patients with solid tumors. Eligible participants with confirmed or suspected melanoma, hepatocellular carcinoma, lung cancer, pancreatic cancer, breast cancer, or ovarian cancer will undergo 68Ga-SorB PET/CT imaging. The imaging findings will be compared with standard-of-care 18F-FDG PET/CT, using pathology results and/or clinical follow-up as the reference standard. The primary objectives are to evaluate the safety and tolerability of 68Ga-SorB, assess imaging feasibility, and characterize tumor uptake using quantitative PET parameters, including SUVmax and tumor-to-background ratio (TBR). Secondary exploratory objectives include comparing lesion detection between 68Ga-SorB PET/CT and 18F-FDG PET/CT, assessing diagnostic sensitivity and specificity, evaluating imaging characteristics across different tumor types, and exploring the correlation between Sortilin expression and tracer uptake. This study will provide preliminary clinical evidence supporting the development of Sortilin-targeted molecular imaging and future theranostic applications.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Hepatocellular Carcinoma
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Breast Carcinoma
Pancreatic Cancer
Ovarian Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Demographics
Lab requirements
Blood counts
white blood cell count ≥ 4.0 × 10^9/l or absolute neutrophil count ≥ 1.5 × 10^9/l; platelet count ≥ 100 × 10^9/l; hemoglobin ≥ 90 g/l
Kidney function
blood urea nitrogen and serum creatinine ≤ 1.5 × uln
Liver function
total bilirubin ≤ 1.5 × uln; alt and ast ≤ 2.5 × uln (or ≤ 5 × uln for participants with liver metastases); alp ≤ 2.5 × uln (or ≤ 4.5 × uln for participants with bone or liver metastases)
Cardiac function
normal cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07760012 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages